• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 483204 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1413778093 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1413778093 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Nektar Therapeutics: 52-Week High Recently Eclipsed (NKTR)

Published on Fri, 04/19/2013 - 14:16
By Peter Chu

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded today at $11.34, breaking its 52-week high. So far today approximately 878,000 shares have been exchanged, as compared to an average 30-day volume of 834,000 shares.

Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

Nektar Therapeutics share prices have moved between a 52-week high of $11.34 and a 52-week low of $5.65 and are now trading 96% above that low price at $11.06 per share. Over the past week, the 200-day moving average (MA) has gone up 0.6% while the 50-day MA has advanced 1.6%.

There is potential upside of 8.5% for shares of Nektar Therapeutics based on a current price of $11.06 and an average consensus analyst price target of $12.00. The stock should discover initial support at its 50-day moving average (MA) of $10.03 and subsequent support at its 200-day MA of $8.87.

By Peter Chu
pchu@fnno.com

Latest News from FNNO

McCormick & Co Earnings Hindsight: Down ...

When McCormick & Co (NYSE:MKC) reported earnings two weeks ago on October 2nd, 2014, an ...

Shares of Strayer Education Have Risen A...

Shares of Strayer Education (NASDAQ:STRA) traded today at $64.79, breaking its 52-week ...

Shares of Sonic Rise Above Previous 52-W...

Shares of Sonic (NASDAQ:SONC) traded today at $23.96, breaking its 52-week high. So fa ...

Shares of Sciclone Pharmaceuticals Rise ...

Shares of Sciclone Pharmaceuticals (NASDAQ:SCLN) traded at a new 52-week high today of ...

Shares of Regeneron Pharmaceuticals Rise...

Regeneron Pharmaceuticals (NASDAQ:REGN) traded today at a new 52-week high of $376.88. ...

Shares of RadNet Have Risen Above Previo...

Shares of RadNet (NASDAQ:RDNT) traded at a new 52-week high today of $8.72. Approximat ...

Recent 52-Week High Exceeded in Shares o...

The Pantry (NASDAQ:PTRY) traded today at a new 52-week high of $24.55. So far today ap ...

Nestle Looks to Continue to Trade Below ...

Shares of Nestle (NASDAQ:NSRGY) traded today at $65.79, breaking its 52-week low. This ...